Cardiol Therapeutics Hits Phase III MAVERIC Enrollment Target Early, Expands Pivotal Recurrent Pericarditis Trial to 150 Patients
核心洞察
Cardiol Therapeutics enrolled 110 patients in the pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis (搜索), reaching its original target ahead of end-of-September guidance.
A blinded review showed fewer pericarditis recurrences than anticipated, prompting the MAVERIC Steering Committee to recommend expanding enrollment to up to 150 patients.
The expansion aims to preserve the trial's planned statistical power and support a more robust assessment of CardiolRx's efficacy in reducing recurrence risk.
Cardiol Therapeutics has enrolled 110 patients in MAVERIC, its pivotal Phase III trial of CardiolRx in recurrent pericarditis (搜索), reaching the study's original recruitment target ahead of the company's end-of-September guidance. As of September 23, 2026, the randomized, double-blind, placebo-controlled, multi-center trial had met that milestone, and the company now plans to expand enrollment to up to 150 patients.
The decision to expand followed a blinded review of events in MAVERIC patients randomized 1:1 to CardiolRx or placebo, which showed a lower level of pericarditis recurrence than anticipated.
"A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx or placebo shows a lower level of pericarditis recurrence than anticipated, an observation we view as encouraging, particularly as we are not aware of changes in routine clinical practice that would explain this finding," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
The MAVERIC Steering Committee recommended the enrollment expansion to capture sufficient events for a robust assessment of CardiolRx's potential to reduce recurrence risk. Elsley said the planned expansion is designed to support the event count needed to preserve the trial's planned statistical power.
Endpoint Design and Regulatory Status
MAVERIC's primary efficacy analysis will assess time to a first new episode of pericarditis recurrence, evaluating the ability of CardiolRx to delay or prevent recurrence over time. The design aligns with the primary endpoint used in the pivotal trial of the only FDA-approved therapy for recurrent pericarditis (搜索). The proportion of patients free from a new episode of recurrent pericarditis at the end of the study will be assessed as a secondary endpoint.
The U.S. Food and Drug Administration has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, including recurrent pericarditis (搜索).
Mechanism and Disease Context
CardiolRx is Cardiol's lead small-molecule drug candidate and modulates inflammasome pathway (搜索) activation, an intracellular innate immune system response that the company says plays an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure (搜索).
Recurrent pericarditis (搜索) is an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue. These symptoms can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
The MAVERIC program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299).
Timeline and Broader Pipeline
Topline results from MAVERIC are now anticipated in mid-2027, compared with previous Q1 2027 guidance. Cardiol said its existing capital is expected to fund completion of MAVERIC, with cash runway extending into Q1 2028.
Beyond recurrent pericarditis (搜索), CardiolRx was studied in the ARCHER program in acute myocarditis (搜索), an important cause of acute and fulminant heart failure (搜索) in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The completed Phase II ARCHER study (NCT05180240) evaluated the safety, tolerability, and efficacy of CardiolRx in that patient population.
The company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure (搜索). Cardiol notes that heart failure is a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.